Vigil Neuroscience (Nasdaq:VIGL) - 주가, 뉴스 및 분석

VIGL 주식 개요

임상 단계의 생명공학 회사인 비질 뉴로사이언스(Vigil Neuroscience, Inc.)는 뇌의 감시 면역 세포인 미세아교세포의 경계를 회복하여 희귀 및 일반적인 신경 퇴행성 질환의 치료법을 개발하는 데 주력하고 있습니다. 자세한 내용

VIGL 기본 분석
눈송이 점수
가치 평가	2/6
미래 성장	2/6
과거 실적	0/6
재무 상태	6/6
배당금	0/6

보상

수익은 연간 77.87% 증가할 것으로 예상됩니다.

위험 분석

수익이 1백만 달러 미만인 경우 ( $0 )

현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.

지난 1년 동안 주주가 희석되었습니다.

Vigil Neuroscience, Inc. 경쟁사

Protalix BioTherapeutics

NYSEAM:PLX

US$124.4m

Cidara Therapeutics

NasdaqCM:CDTX

US$143.8m

InflaRx

NasdaqGS:IFRX

US$122.5m

Decibel Therapeutics

NasdaqGS:DBTX

US$124.3m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Vigil Neuroscience
과거 주가
현재 주가	US$3.19
52주 최고치	US$6.06
52주 최저치	US$2.47
베타	1.93
11개월 변경	-10.89%
3개월 변경 사항	-8.60%
1년 변경 사항	2.90%
33년 변화	n/a
5년 변화	n/a
IPO 이후 변화	-74.78%

최근 뉴스 및 업데이트

We Think Vigil Neuroscience (NASDAQ:VIGL) Needs To Drive Business Growth Carefully

Oct 17

Recent updates

We Think Vigil Neuroscience (NASDAQ:VIGL) Needs To Drive Business Growth Carefully

Oct 17

We're Keeping An Eye On Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Rate

May 30

Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans?

Feb 01

Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans?

Oct 14

Here's Why We're Not Too Worried About Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Situation

Jun 27

Here's Why We're Not Too Worried About Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Situation

Mar 14

Here's Why We're Not Too Worried About Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Situation

Nov 29

주주 수익률

	VIGL	US Biotechs	US 마켓
7D	0%	2.5%	2.2%
1Y	2.9%	16.1%	31.6%

수익률 대 산업: VIGL 지난 1년 동안 16.1 %를 반환한 US Biotechs 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: VIGL 지난 1년 동안 31.6 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is VIGL's price volatile compared to industry and market?
VIGL volatility
VIGL Average Weekly Movement	8.3%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

안정적인 주가: VIGL 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.

시간에 따른 변동성: VIGL 의 주간 변동성은 지난 1년 동안 14% 에서 8% 로 감소했습니다.

회사 소개

설립	직원	CEO	웹사이트
2020	66	Ivana Magovcevic-Liebisch	www.vigilneuro.com

임상 단계의 생명공학 기업인 비질 뉴로사이언스(Vigil Neuroscience, Inc.)는 뇌의 감시 면역 세포인 미세아교세포의 경계 기능을 회복하여 희귀 및 흔한 신경 퇴행성 질환의 치료제를 개발하는 데 주력하고 있습니다. 주요 후보물질은 골수성 세포 2에서 발현되는 인간 유발 수용체를 표적으로 하는 인간 단일클론 항체 작용제인 VGL101(일루자네바트)이며, 희귀하고 치명적인 신경 퇴행성 질환인 축삭 구상돌기 및 색소 아교세포(ALSP)가 있는 성인 발병 백뇌병 환자를 대상으로 2상 시험을 진행 중입니다. 또한 회사는 미세아교세포 기능 장애와 관련된 일반적인 신경 퇴행성 질환을 치료하기 위해 경구용 저분자 TREM2 작용제인 VG-3927을 개발 중이며, 유전적으로 정의된 하위 집단의 알츠하이머병에 초점을 맞춰 임상 1상 시험에서 평가 중입니다.

Vigil Neuroscience, Inc. 기본 사항 요약

Vigil Neuroscience 의 수익과 매출은 시가총액과 어떻게 비교하나요?
VIGL 기본 통계
시가총액	US$130.26m
수익(TTM)	-US$82.60m
수익(TTM)	n/a

0.0x

P/S 비율

-1.6x

P/E 비율

VIGL 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
VIGL 손익 계산서(TTM)
수익	US$0
수익 비용	US$0
총 이익	US$0
기타 비용	US$82.60m
수익	-US$82.60m

최근 보고된 수익

Sep 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-2.02
총 마진	0.00%
순이익 마진	0.00%
부채/자본 비율	0%

VIGL 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

VIGL 주식 개요

보상

위험 분석

Vigil Neuroscience, Inc. 경쟁사

NYSEAM:PLX

US$124.4m

NasdaqCM:CDTX

US$143.8m

NasdaqGS:IFRX

US$122.5m

NasdaqGS:DBTX

US$124.3m

가격 내역 및 성능

최근 뉴스 및 업데이트

Price target increased by 9.8% to US$17.57

We Think Vigil Neuroscience (NASDAQ:VIGL) Needs To Drive Business Growth Carefully

General Counsel & Corporate Secretary notifies of intention to sell stock

Vigil Neuroscience, Inc. Announces U.S. Food and Drug Administration Removal the Partial Clinical Hold on its Ongoing Phase 1 Clinical Trial of VG-3927

New major risk - Financial position

Vigil Neuroscience, Inc. Announces Interim Data from Its Ongoing Phase 1 Clinical Trial Evaluating Vv-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer's Disease

Recent updates

Price target increased by 9.8% to US$17.57

We Think Vigil Neuroscience (NASDAQ:VIGL) Needs To Drive Business Growth Carefully

General Counsel & Corporate Secretary notifies of intention to sell stock

Vigil Neuroscience, Inc. Announces U.S. Food and Drug Administration Removal the Partial Clinical Hold on its Ongoing Phase 1 Clinical Trial of VG-3927

New major risk - Financial position

Vigil Neuroscience, Inc. Announces Interim Data from Its Ongoing Phase 1 Clinical Trial Evaluating Vv-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer's Disease

Vigil Neuroscience, Inc. Provides Update on Clinical Development Strategy to Pursue Potential Accelerated Approval Pathway for Iluzanebart in ALSP

Vigil Neuroscience, Inc.(NasdaqGS:VIGL) dropped from Russell Small Cap Comp Value Index

Vigil Neuroscience, Inc. announced that it expects to receive $39.99997 million in funding from Sanofi Pasteur Biologics, LLC, Aventis Inc.

Vigil Neuroscience, Inc. announced that it has received $3.999997 million in funding from Sanofi Pasteur Biologics, LLC

New major risk - Share price stability

We're Keeping An Eye On Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Rate

New major risk - Revenue and earnings growth

Price target increased by 8.4% to US$18.57

New minor risk - Market cap size

Vigil Neuroscience, Inc., Annual General Meeting, Jun 05, 2024

Vigil Neuroscience, Inc. Presents Key Findings from Illuminate & Ignite Studies in ALSP At the 2024 American Academy of Neurology Annual Meeting

New minor risk - Shareholder dilution

Price target increased by 10% to US$18.86

New major risk - Revenue and earnings growth

Vigil Neuroscience, Inc. Announces Executive Changes

New minor risk - Market cap size

Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans?

New minor risk - Market cap size

Price target decreased by 14% to US$17.13

Vigil Neuroscience, Inc. Reports Positive Interim Data from Phase 2 Ignite Proof-Of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE

New major risk - Revenue and earnings growth

Vigil Neuroscience, Inc. Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating Vv-3927, a Small Molecule Trem2 Agonist, for Potential Treatment of Alzheimer's Disease

Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans?

Vigil Neuroscience, Inc Provides an Update on the Small Molecule TREM2 Agonist, VG-3927

Vigil Neuroscience, Inc. Receives Positive Opinion from European Medicines Agency on Orphan Drug Designation for Vgl101 for the Treatment of ALSP

Vigil Neuroscience, Inc. Presents VGL101 Complete Phase 1 Data and Phase 2 Ignite Trial Design at the 2023 American Neurological Association Annual Meeting

New major risk - Share price stability

Vigil Neuroscience, Inc. Appoints Christopher J. Silber, M.D. as Chief Medical Officer

Here's Why We're Not Too Worried About Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Situation

Vigil Neuroscience, Inc. Appoints Samantha Budd Haeberlein to Its Board of Directors

Here's Why We're Not Too Worried About Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Situation

Vigil Neuroscience, Inc. Announces Resignation of Shaan Gandhi, from Member of Board of Directors

High number of new and inexperienced directors

Vigil Neuroscience, Inc. Announces Executive Changes

Here's Why We're Not Too Worried About Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Situation

Chief Medical Officer notifies of intention to sell stock

Vigil Neuroscience Announces Interim Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating VGL101 in Healthy Volunteers Supporting Phase 2 Initiation in ALSP

Vigil Neuroscience Receives FDA Fast Track Designation for VGL101 for the Treatment of Patients with ALSP

Vigil draws bullish view at Wedbush on upcoming readout for lead asset

Vigil Neuroscience, Inc. announced that it has received $74.999705 million in funding from Deep Track Capital, LP, BVF Partners L.P., Deerfield Management Company, L.P. Series C, Dafna Capital Management, LLC, The Invus Group, LLC

Vigil Neuroscience, Inc. announced that it expects to receive $74.999705 million in funding from Deep Track Capital, LP, BVF Partners L.P., Deerfield Management Company, L.P. Series C, Dafna Capital Management, LLC, The Invus Group, LLC

Vigil Neuroscience announces $75M PIPE financing

Vigil Neuroscience Appoints Suzanne Bruhn to Its Board of Directors

We're Hopeful That Vigil Neuroscience (NASDAQ:VIGL) Will Use Its Cash Wisely

Vigil Neuroscience, Inc.(NasdaqGS:VIGL) dropped from Russell 2000 Growth Index

Vigil Neuroscience, Inc. Expands VGL101 Phase 1 Trial to Australia

Vigil Neuroscience, Inc. Appoints Christopher Verni as General Counsel and Mary Thistle to Its Board of Directors

Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Invest In Growth?

Vigil Neuroscience, Inc. has completed an IPO in the amount of $98 million.

주주 수익률

가격 변동성

회사 소개

Vigil Neuroscience, Inc. 기본 사항 요약